(Total Views: 900)
Posted On: 10/25/2020 5:46:01 AM
Post# of 153880
Washington’s plunging CytoDyn (CYDY) needs more time to develop leronlimab for severe-to-critical COVID-19 patients
October 24, 2020 Jack Dawkins
COVID-19 vaccine makers are still facing a hard time to fight the pandemic as the second wave is taking thousands of lives. This fall no vaccine is ready to be salvation despite pouring billions in biotech firms that are in hurry to release their beasts to end the modern plague. CytoDyn’s (CYDY) leronlimab or PRO 140 is still the strongest candidate to neutralize COVID-19’s power in killing the immunity of severe to critical patients.
Like Relief Therapeutics the company hopes to raise funds from external sources to make the revenue rise further for covering all the expenses and costs but that can be only a dream not a goal amid unpredictable situations when scientists need to burn more cash.
At the end of June, the stock reached its 2020’s peak after the media announced the start of clinical trials of leronlimab. However, CYDY might rise even without the work of scientists. Announcing even a partnership deal or acquisition can make the stock soar more than double as the short term investors buy right away. Friday’s trade led to an 8.21% fall which could lead to steady growth next week.
https://ownsnap.com/washingtons-plunging-cyto...-patients/
I saw this on a facebook group. I have never heard of Own snap.
October 24, 2020 Jack Dawkins
COVID-19 vaccine makers are still facing a hard time to fight the pandemic as the second wave is taking thousands of lives. This fall no vaccine is ready to be salvation despite pouring billions in biotech firms that are in hurry to release their beasts to end the modern plague. CytoDyn’s (CYDY) leronlimab or PRO 140 is still the strongest candidate to neutralize COVID-19’s power in killing the immunity of severe to critical patients.
Like Relief Therapeutics the company hopes to raise funds from external sources to make the revenue rise further for covering all the expenses and costs but that can be only a dream not a goal amid unpredictable situations when scientists need to burn more cash.
At the end of June, the stock reached its 2020’s peak after the media announced the start of clinical trials of leronlimab. However, CYDY might rise even without the work of scientists. Announcing even a partnership deal or acquisition can make the stock soar more than double as the short term investors buy right away. Friday’s trade led to an 8.21% fall which could lead to steady growth next week.
https://ownsnap.com/washingtons-plunging-cyto...-patients/
I saw this on a facebook group. I have never heard of Own snap.
(3)
(0)
